Overview

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

Status:
Completed

Trial end date:
2017-09-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double blind, 3 arm (1:1:1) study in subjects with 1st-line metastatic pancreatic ductal adenocarcinoma. The purpose is to test the efficacy and safety of demcizumab, when given in combination with gemcitabine and Abraxane® compared to placebo. The administration of gemcitabine and Abraxane® is a standard treatment for patients with metastatic pancreatic ductal adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

OncoMed Pharmaceuticals, Inc.

Collaborator:

Celgene Corporation

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel